Morphic Holding, Inc. (NASDAQ:MORF) Director Fund V. L.P. Omega sold 9,543 shares of the company’s stock in a transaction on Monday, April 5th. The shares were sold at an average price of $62.11, for a total value of $592,715.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of MORF opened at $60.68 on Thursday. Morphic Holding, Inc. has a 1 year low of $12.09 and a 1 year high of $93.00. The stock has a market capitalization of $1.97 billion, a PE ratio of -38.90 and a beta of 1.01. The stock has a 50-day simple moving average of $57.78 and a 200-day simple moving average of $37.39.
Morphic (NASDAQ:MORF) last issued its quarterly earnings results on Sunday, February 28th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.07). The company had revenue of $5.90 million for the quarter, compared to the consensus estimate of $8.00 million. Research analysts forecast that Morphic Holding, Inc. will post -1.28 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the stock. Lazard Asset Management LLC acquired a new stake in Morphic in the fourth quarter valued at $66,000. Citigroup Inc. raised its position in shares of Morphic by 327.3% during the 4th quarter. Citigroup Inc. now owns 2,816 shares of the company’s stock worth $94,000 after acquiring an additional 2,157 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Morphic by 10.5% during the third quarter. JPMorgan Chase & Co. now owns 5,105 shares of the company’s stock worth $140,000 after purchasing an additional 487 shares during the last quarter. Virtus ETF Advisers LLC acquired a new position in Morphic in the fourth quarter valued at approximately $295,000. Finally, Russell Investments Group Ltd. purchased a new position in Morphic in the fourth quarter valued at approximately $395,000. 61.49% of the stock is currently owned by hedge funds and other institutional investors.
Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4Ã7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and MORF-720 and MORF-627, which is in the preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.
Featured Story: Gross Domestic Product (GDP)
Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.